CA2340176A1 - Inhibition of pathogenic processes related to tissue trauma - Google Patents

Inhibition of pathogenic processes related to tissue trauma Download PDF

Info

Publication number
CA2340176A1
CA2340176A1 CA002340176A CA2340176A CA2340176A1 CA 2340176 A1 CA2340176 A1 CA 2340176A1 CA 002340176 A CA002340176 A CA 002340176A CA 2340176 A CA2340176 A CA 2340176A CA 2340176 A1 CA2340176 A1 CA 2340176A1
Authority
CA
Canada
Prior art keywords
group
inhibition
expression
halofuginone
collagen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002340176A
Other languages
English (en)
French (fr)
Inventor
Mark Pines
Israel Vlodavsky
Arnon Nagler
Eli Hazum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hadasit Medical Research Services and Development Co
Agricultural Research Organization of Israel Ministry of Agriculture
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2340176A1 publication Critical patent/CA2340176A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002340176A 1998-08-13 1999-08-13 Inhibition of pathogenic processes related to tissue trauma Abandoned CA2340176A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IL125790 1998-08-13
IL12579098 1998-08-13
US13714599P 1999-06-01 1999-06-01
US60/137,145 1999-06-01
PCT/IL1999/000440 WO2000009070A2 (en) 1998-08-13 1999-08-13 Inhibition of pathogenic processes related to tissue trauma

Publications (1)

Publication Number Publication Date
CA2340176A1 true CA2340176A1 (en) 2000-02-24

Family

ID=26323693

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002340176A Abandoned CA2340176A1 (en) 1998-08-13 1999-08-13 Inhibition of pathogenic processes related to tissue trauma

Country Status (8)

Country Link
EP (1) EP1109559B1 (https=)
JP (1) JP2002522462A (https=)
AT (1) ATE307586T1 (https=)
AU (1) AU756437B2 (https=)
CA (1) CA2340176A1 (https=)
DE (1) DE69927987T2 (https=)
ES (1) ES2255286T3 (https=)
WO (1) WO2000009070A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL143366A0 (en) * 2001-05-24 2002-04-21 Harasit Medical Res Services & Treatment of renal fibrosis
US20060258692A1 (en) * 2002-10-31 2006-11-16 Mark Pines Quinazolinone compositions for regulation of gene expression related to pathological processes
RU2243778C2 (ru) * 2003-02-18 2005-01-10 Московский городской научно-исследовательский институт скорой помощи им. Н.В. Склифосовского Способ лечения последствий травматического и интраоперационного повреждения тканей у больных с политравмой
AU2007238816B2 (en) * 2006-04-10 2012-12-06 President And Fellows Of Harvard College Methods for modulating formation and progression of cellulite
US8410120B2 (en) 2007-01-21 2013-04-02 Mark Pines Composition and method for treating or preventing skeletal muscle fibrosis
US9284297B2 (en) 2008-08-11 2016-03-15 President And Fellows Of Harvard College Halofuginone analogs for inhibition of tRNA synthetases and uses thereof
US20130323763A1 (en) 2011-02-10 2013-12-05 Sapporo Medical University Method for diagnosing acute lung injury
AU2013207796B2 (en) 2012-01-13 2017-04-27 President And Fellows Of Harvard College Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
WO2019237125A1 (en) 2018-06-08 2019-12-12 The General Hospital Corporation Inhibitors of prolyl-trna-synthetase

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320124A (en) * 1964-07-20 1967-05-16 American Cyanamid Co Method for treating coccidiosis with quinazolinones
DE2934069A1 (de) * 1979-08-23 1981-03-12 Hoechst Ag, 6000 Frankfurt Mittel gegen theileriosen und seine verwendung.
JPH08510251A (ja) * 1993-05-07 1996-10-29 ビー マーゴリン、ソロモン 線維症の病変の修復と予防のための組成物および方法
CA2113229C (en) * 1994-01-11 1999-04-20 Mark Pines Anti-fibrotic quinazolinone-containing compositions and methods for the use thereof
IL110831A (en) * 1994-08-31 1998-12-27 Hadasit Med Res Service Pharmaceutical compositions containing quinazolinone derivatives for preventing restenosis
JPH0971586A (ja) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd 新規な二環性縮合イミダゾール誘導体
EP0956354B1 (en) * 1996-07-03 2009-01-14 Université de Liège Recombinant n-proteinase, and the production, methods and uses thereof
EP1806131A3 (en) * 1996-07-22 2007-08-01 Renovo Limited Use of sex steroid function modulators to treat wounds and fibrotic disorders
DE69716460T2 (de) * 1996-12-04 2003-06-26 Renovo Ltd., Manchester Wundheilung und behandlung von fibrose
US5852024A (en) * 1997-02-11 1998-12-22 Hadasit Treatment and prevention of adhesions
US6028075A (en) * 1997-02-11 2000-02-22 Pines; Mark Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
DE19951702A1 (de) * 1999-10-27 2001-05-03 Aventis Pharma Gmbh Verwendung von 2-Amino-3,4-dihydro-chinazolinen zur Herstellung eines Medikaments zur Behandlung oder Prophylaxe von durch ischämischen Zuständen bewirkten Krankheiten

Also Published As

Publication number Publication date
ATE307586T1 (de) 2005-11-15
AU5191499A (en) 2000-03-06
WO2000009070A3 (en) 2000-10-19
WO2000009070A2 (en) 2000-02-24
ES2255286T3 (es) 2006-06-16
AU756437B2 (en) 2003-01-16
EP1109559B1 (en) 2005-10-26
JP2002522462A (ja) 2002-07-23
EP1109559A2 (en) 2001-06-27
DE69927987D1 (de) 2005-12-01
DE69927987T2 (de) 2006-11-09
EP1109559A4 (en) 2002-05-08

Similar Documents

Publication Publication Date Title
US12268710B2 (en) Method of treating severe forms of pulmonary hypertension
EP0815215A2 (en) An antisense transcript associated to tumor cells having a t(14;18) translocation and oligodeoxynucleotides useful in the diagnosis and treatment of said tumor cells
US20160168577A1 (en) Clusterin Antisense Therapy for Treatment of Cancer
Meng et al. Transplantation of mesenchymal stem cells overexpressing IL10 attenuates cardiac impairments in rats with myocardial infarction
AU756437B2 (en) Inhibition of pathogenic processes related to tissue trauma
Klamer et al. Using small molecule GSK3β inhibitors to treat inflammation
CA2380678A1 (en) Treatment of inflammatory or malignant disease using dnazymes
US20070010538A1 (en) Inhibition of pathogenic processes related to tissue trauma
US20220160772A1 (en) Targeting of src-3 in immune cells as an immunomodulatory therapeutic for the treatment of cancer
KR20230039781A (ko) 크릴새우 추출물을 포함하는 근육 질환의 예방 또는 치료용 약학 조성물
IL141408A (en) Compositions for treating cardiac fibrosis comprising halfuginone derivatives
US8193158B2 (en) Use of apoptosis-specific eIF-5A siRNA to down regulate expression of proinflammatory cytokines to treat sepsis
SK83895A3 (en) Oligonucleotides for inhibition of expression of izoprenyl-proteineous transferases
CN113476606B (zh) Upk1a-as1抑制剂在制备抗肿瘤药物中的应用
KR20240086713A (ko) Gas5 억제제 및 smarca4 억제제를 유효성분으로 포함하는 간암 예방 또는 치료용 약학 조성물
KR101486248B1 (ko) Ｄｎａ 메틸화 저해제를 포함하는 상염색체 우성 다낭신 개선 또는 치료용 약학 조성물
Naora et al. Antisense sequences of the nbl gene induce apoptosis in the human promyelocytic leukemia cell line HL-60
Provinciali et al. Nutritional modulators of cellular senescence in vitro
Long et al. The role of panax notoginseng saponins on neuronal oxidative stress and autophagy response in craniocerebral injury model rats
Gouda et al. Enhanced cytotoxicity of sorafenib in hepatocellular carcinoma through synergistic combination with naringenin: a molecular and cellular perspective
JP7847874B2 (ja) ｍｉＲ１４５阻害剤を有効成分として含む心筋梗塞の治療用組成物
EP1911449A1 (en) Anti-tumor agent comprising 6'-amidino-2'-naphthyl4- guanidinobenzoate or salt thereof
US20140371299A1 (en) Use of Apoptosis-Specific elF-5A siRNA to Down Regulate Expression of Proinflammatory Cytokines to Treat Sepsis
TW422699B (en) Pharmaceutical composition for cell differentiation and the uses thereof in cancer therapy and prevention
KR20230046965A (ko) 플루록시피르-1-메틸헵틸 에스터를 유효성분으로 포함하는 혈관신생 억제용 약학적 조성물

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued